Irvine, CA (PRWEB) March 25, 2015 <\/p>\n
Proove Biosciences, a commercial and research leader in Personalized Medicine, is excited to announce the success of their commercially supported symposium, Personalized Medicine: Incorporating Genetic Testing to Optimize the Management of Pain, at the 31st Annual American Academy of Pain Medicine conference in National Harbor, Maryland on Thursday, March 19th, 2015. <\/p>\n
The symposiums faculty, which consisted of former AAPM President Lynn Webster, M.D., former Florida Society of Interventional Pain Physicians President Sanford Silverman, M.D., and local D.C. pain physician Abraham Cherrick, M.D. presented supporting data for Prooves proprietary genetic tests; tests that are designed to objectively guide clinical decisions in screening for opioid contraindications, improve medication efficacy, and avoid adverse drug events. <\/p>\n
Most people don't realize the tremendous variability people have to the same painful stimulus. This is why some people hurt while other don't seem to be bothered by the same type of trauma. states Lynn Webster, M.D. It is now clear that pain sensitivity is significantly influenced by our genes. Scientist are able to identify pain reducing genes and pain elaboration genes. <\/p>\n
Webster, M.D. continues, Although it is only an emerging field it is exciting because genotyping may allow us to identify people who are more likely to respond to one drug than another. Even more importantly, genotyping offers potential to identify individuals who may have side effects or toxicity to certain drugs. This means genetic testing can lead to safer and more effective therapy. Personalized medicine uses genetic testing to optimize pain management and many other areas in medicine. <\/p>\n
About Proove Biosciences Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We seek to realize a future when clinicians look back and wonder how they couldve ever prescribed medications without knowing how a patient would respond. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http:\/\/www.proove.com<\/a> or call toll free 855-PROOVE-BIO (855-776-6832). <\/p>\n <\/p>\n Read the original post:<\/p>\n Proove Biosciences Hosts Symposium on Incorporating Genetic Testing to Optimize the Management of Pain<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Irvine, CA (PRWEB) March 25, 2015 Proove Biosciences, a commercial and research leader in Personalized Medicine, is excited to announce the success of their commercially supported symposium, Personalized Medicine: Incorporating Genetic Testing to Optimize the Management of Pain, at the 31st Annual American Academy of Pain Medicine conference in National Harbor, Maryland on Thursday, March 19th, 2015. The symposiums faculty, which consisted of former AAPM President Lynn Webster, M.D., former Florida Society of Interventional Pain Physicians President Sanford Silverman, M.D., and local D.C. Continue reading